Fulcrum Therapeutics (FULC) Total Non-Current Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Total Non-Current Liabilities for 9 consecutive years, with $13.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Total Non-Current Liabilities fell 8.45% year-over-year to $13.1 million; the TTM figure through Jun 2026 stood at $13.1 million (down 8.45% YoY), while the FY2025 annual figure was $17.1 million, down 2.29% from the prior year.
• Total Non-Current Liabilities declined to $13.1 million in Q2 2026 per FULC's latest filing, from $13.3 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $34.3 million in Q2 2022 and bottomed at $13.1 million in Q2 2026.
• Historically, Total Non-Current Liabilities has averaged $20.5 million across 5 years, with a median of $20.3 million in 2024.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities advanced 17.41% — and 2025, when it declined 29.63%.
• Fulcrum Therapeutics' Total Non-Current Liabilities stood at $27.5 million in 2022, then declined by 19.03% to $22.3 million in 2023, then decreased by 21.6% to $17.5 million in 2024, then dropped by 2.29% to $17.1 million in 2025, then decreased by 23.58% to $13.1 million in 2026.
• Business Quant data shows FULC's Total Non-Current Liabilities at $13.1 million in Q2 2026, $13.3 million in Q1 2026, and $17.1 million in Q4 2025.